Skip to content
LGBTQIA, Medical Health Aged Care

Monash Experts: Letting communities lead on World AIDS Day – Friday 1 December

Monash University 2 mins read

Friday 1 December is World AIDS Day and to mark the pivotal impact communities have had in shaping the HIV response, this year’s theme is ‘Let communities lead’. 

World AIDS Day reflects on progress made to date, raises awareness about the challenges that remain to achieve the goal of ending AIDS by 2030 and mobilises all stakeholders to jointly redouble efforts to ensure the success of the HIV response.

Available to comment:

Professor Jennifer Hoy, Director of HIV Medicine, Department of Infectious Diseases, Alfred Hospital and Monash University
Contact details: +61 3 9903 4840, or Jennifer.Hoy@monash.edu 

  • Current HIV treatments
  • Ageing with HIV
  • HIV and stigma

The following can be attributed to Professor Hoy:

“Current treatment for HIV has enabled people with HIV to live near normal life expectancy. However, they experience excess co-morbidities (heart attacks, stroke, diabetes, cancers) because of chronic inflammation associated with immune responses helping to control HIV. Ageing with HIV should be celebrated but also requires more support from healthcare providers.

“Antiretroviral treatment allows people with HIV to achieve extremely low levels of virus in their blood – called ‘undetectable’ HIV, and multiple large global studies have shown it is not possible to transmit HIV to others at these low levels. So, treatment of HIV is one of the pillars of attaining virtual elimination of new HIV infections by 2030. U=U – Undetectable = untransmittable

“Despite these great results, people with HIV still experience significant stigma – in the community, and in healthcare settings. Community-led responses are vital in building resilience in people with HIV, restoring good quality of life and supporting people with HIV to navigate safe pathways to good health.”

Associate Professor James McMahon, Head of Clinical Research Unit, Department of Infectious Diseases, The Alfred, Associate Professor, Central Clinical School, Monash University,
Contact details: +61 3 9903 4840 or media@monash.edu  
Read more of Associate Professor McMahon’s commentary at Monash Lens 

  • HIV and AIDS
  • His team’s research towards a HIV cure 
  • The need for access to current treatments

The following can be attributed to Associate Professor McMahon:

“Amazing progress has been made in the HIV response, but gaps remain. We need to maximise diagnosis in high risk populations, providing prevention (pre-exposure prophylaxis or PrEP) and access to testing for high risk and hard to reach populations.

“We continue to work on new treatment options, including long acting antiretroviral therapy (ART). We also need to advocate for access to free ART for all Australians with HIV to maximise treatment uptake and adherence to treatment.”

For more Monash media stories visit our news & events site: monash.edu/news
For any other topics on which you may be seeking expert comment, contact the Monash University Media Unit on +61 3 9903 4840 or media@monash.edu

More from this category

  • Medical Health Aged Care
  • 16/01/2025
  • 06:05
Royal Australian College of GPs

ADHD reform more urgent in NSW with psychiatrists’ workforce crisis

The Royal Australian College of GPs is urging the New South Wales Government to prioritise reforms to improve access to support and treatment for people with attention deficit hyperactivity disorder (ADHD) from GPs after the mass resignation of psychiatrists. Around 200 psychiatrists in NSW's public health system have submitted their resignations amid an ongoing pay dispute with the state government. RACGP New South Wales Chair Dr Rebekah Hoffman said: “GPs should be able to initiate and prescribe medications for people living with ADHD, and manage their care. Allowing GPs to give more support to people living with ADHD will improve…

  • Medical Health Aged Care
  • 16/01/2025
  • 05:00
GlaxoSmithKline

Local scientific discovery Omjarra (momelotinib) now TGA approved for Australians with rare bone marrow cancer

Embargoed: 06.00am Thursday 16th January 2025, MELBOURNE, AUSTRALIA Omjjara (momelotinib) was discovered by Melbourne scientists in 2005.1 Today’s TGA approval follows its recent FDA approval and makes it one of only a handful of original Australian scientific discoveries to secure both milestones.1-6 Omjjara is a once daily pill indicated to treat disease-related consequences of primary or secondary myelofibrosis including spleen enlargement and moderate to severe anaemia.7 Myelofibrosis is a rare bone marrow cancer with an average survival of 5-7 years.7-8 GSK Australia welcomes the Therapeutic Goods Administration (TGA) approval of Omjjara - a local scientific discovery now providing the first…

  • Medical Health Aged Care
  • 15/01/2025
  • 20:54
Glaxo SmithKline

Local scientific discovery Omjarra (momelotinib) TGA approved for Australians with rare bone marrow cancer

MELBOURNE PHOTO-FILMING OPPORTUNITY: THURSDAY 16TH JANUARY 2025 DATE: Thursday 16th January 2025 TIME: 10.30 – 11.30am LOCATION: 3 Torresdale Road, Toorak, Melbourne INTERVIEWEES: Prof…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.